X0202 SCHEDULE 13G 0001157075 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 03/17/2026 0001339005 FEMASYS INC 31447E105 3950 JOHNS CREEK COURT SUITE 100 SUWANEE GA 30024 Rule 13d-1(c) PharmaCyte Biotech, Inc. NV 4932825.00 0.00 4932825.00 0.00 4932825.00 N 7.87 CO For Items 5 and 7: Includes (i) 695,537 shares of common stock, par value $0.001 ("Common Stock"), of Femasys Inc. (the "Issuer"), and (ii) Series A warrants immediately exercisable for 4,237,288 shares of Common Stock, subject to a 19.99% beneficial ownership limitation. For Item 11: Based on the quotient obtained by dividing (i) the number of shares of Common Stock beneficially owned by PharmaCyte Biotech, Inc. (the "Reporting Person") by (ii) the sum of (a) 58,479,824 shares of Common Stock outstanding as of November 13, 2025, as reported in the Issuer's 10-Q, filed with the Securities Exchange Commission on November 14, 2025, and (b) 4,237,288 shares of Common Stock issuable upon exercise of the Series A warrants held by the Reporting Person. Introductory Note: This Schedule 13G amends and supplements the Schedule 13D filed with the Securities and Exchange Commission on November 22, 2023 (as amended from time to time, the "Schedule 13D") by PharmaCyte Biotech, Inc., a Nevada corporation (the "Reporting Person"), relating to its beneficial ownership in Femasys Inc. (the "Issuer"). On March 17, 2026, Joshua Silverman, Chairman, Chief Executive Officer and President of the Reporting Person, resigned from the Issuer's Board of Directors. As of the filing of this Schedule 13G, the Reporting Person does not hold the securities with the purpose or effect of changing or influencing control of the Issuer. As such, this Schedule 13G is deemed to amend the Schedule 13D. FEMASYS INC 3950 Johns Creek Court, Suite 100, Suwanee, GA PharmaCyte Biotech, Inc. PharmaCyte Biotech, Inc., 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169. The Reporting Person is a Nevada corporation. Y The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. Percentage ownership is based on 58,479,824 shares of Common Stock outstanding as of November 13, 2025, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2025 filed with the Securities and Exchange Commission on November 14, 2025. The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. The information required by this paragraph is set forth in the cover pages to this Schedule 13G and is incorporated herein by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. PharmaCyte Biotech, Inc. /s/ Joshua N. Silverman 03/18/2026